Categories: News

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place March 23-24, 2021 in a virtual format.

Details of the company’s participation are as follows:

  • KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
    Conference Date: March 23-24, 2021
    Fireside Chat Time/Date: 4:15 p.m. Eastern on Wednesday, March 24, 2021
    Format: Virtual Conference

About Avid Bioservices, Inc.

Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid’s services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

CONTACT: Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
 
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com

Staff

Recent Posts

Adia Labs Launches Turnkey Clinic Model for Chiropractic Practices with BoldMD

Winter Park, Florida--(Newsfile Corp. - December 17, 2025) - Adia Labs, a division of Adia…

1 hour ago

Population Health Partners and dacadoo Announce Strategic Partnership to Advance Digital Health Engagement and Outcome-Based Healthcare

New York and Zurich, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Population Health Partners, L.P., a…

2 hours ago

Population Health Partners and dacadoo Announce Strategic Partnership to Advance Digital Health Engagement and Outcome-Based Healthcare

New York and Zurich, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Population Health Partners, L.P., a…

2 hours ago

Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell

RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation…

2 hours ago

Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell

RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation…

2 hours ago

Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare

Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor…

2 hours ago